APO-MIRTAZAPINE 30 MG
MIRTAZAPINE : 30 MG · DIN 02286629 · APOTEX INC
Health Canada status: MARKETED
What is APO-MIRTAZAPINE?
APO-MIRTAZAPINE 30 MG contains MIRTAZAPINE : 30 MG. It is listed in the Health Canada Drug Product Database under DIN 02286629, held by APOTEX INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 04-Oct-2006. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is APO-MIRTAZAPINE used for?
Symptomatic relief of depressive illness.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02286629 |
|---|---|
| Brand name | APO-MIRTAZAPINE |
| Generic / active ingredient | MIRTAZAPINE : 30 MG |
| Manufacturer | APOTEX INC |
| Strength | 30 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N06AX11 MIRTAZAPINE |
| AHFS class | 28:16.04.92 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 04-Oct-2006 |
| Original market date | 2006-10-04 00:00:00 |
How is it administered?
Initial dose 15 mg daily, preferably in the evening. May increase up to 45 mg/day. Dose changes should occur at intervals of at least one week. Swallow whole with water.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (standard reference to Part I, section 11), but usually 15-30°C.
How is it supplied?
15 mg: Bottles of 30; 30 mg: Bottles of 100; 45 mg: Bottles of 30 and 100.
Contraindications
Hypersensitivity to mirtazapine or any ingredient; concomitant use with Monoamine Oxidase Inhibitors (MAOIs) or within 2 weeks of MAOI cessation.
Warnings and precautions
Risk of suicidal ideation/behaviour; agranulocytosis; QT prolongation/Torsade de Pointes; somnolence; increased appetite/weight gain; hyponatremia; serotonin toxicity.
Is MIRTAZAPINE in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by SANIS HEALTH INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code N06AX11 MIRTAZAPINE. 31 of 64 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-MIRTAZAPINE | 15 MG | TABLET | APOTEX INC | MARKETED | DIN 02286610 |
| APO-MIRTAZAPINE | 45 MG | TABLET | APOTEX INC | MARKETED | DIN 02286637 |
| AURO-MIRTAZAPINE | 15 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02411695 |
| AURO-MIRTAZAPINE | 30 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02411709 |
| AURO-MIRTAZAPINE | 45 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02411717 |
| AURO-MIRTAZAPINE OD | 15 MG | TABLET (ORALLY DISINTEGRATING) | AURO PHARMA INC | MARKETED | DIN 02299801 |
| AURO-MIRTAZAPINE OD | 30 MG | TABLET (ORALLY DISINTEGRATING) | AURO PHARMA INC | MARKETED | DIN 02299828 |
| AURO-MIRTAZAPINE OD | 45 MG | TABLET (ORALLY DISINTEGRATING) | AURO PHARMA INC | MARKETED | DIN 02299836 |
| MIRTAZAPINE | 15 MG | TABLET | SIVEM PHARMACEUTICALS ULC | MARKETED | DIN 02496666 |
| MIRTAZAPINE | 15 MG | TABLET | SANIS HEALTH INC | MARKETED | DIN 02532689 |
Who else supplies MIRTAZAPINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. MIRTAZAPINE appears in 497 registered pack listings across 13 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.